Warren Buffett Detailed Fundamental Analysis

Validea's guru fundamental report indicates that ZOETIS INC (ZTS) receives an 82% rating based on their Warren Buffett-inspired "Patient Investor" model, which favors firms with predictable profitability, low debt, and reasonable valuations; a score above 80% suggests interest in the stock. While ZTS passes most of the model's tests, including earnings predictability, debt service, and return on equity, it fails the return on total capital test.

Analysis

Zoetis Inc. (ZTS) has garnered an 82% rating from Validea's Patient Investor model, which emulates Warren Buffett's strategy of identifying firms with long-term, predictable profitability, low debt, and reasonable valuations. This score, exceeding the 80% threshold, indicates that the model has some interest in ZTS, a large-cap growth stock operating in the Biotechnology & Drugs industry. The company demonstrates strength across several fundamental metrics, passing tests for Earnings Predictability, Debt Service, Return on Equity, Free Cash Flow, Use of Retained Earnings, Share Repurchase, Initial Rate of Return, and Expected Return. However, a notable weakness identified by the model is ZTS's failure to meet the 'Return on Total Capital' criterion. Despite this, the per-ticker sentiment for ZTS is strongly positive at 0.8, suggesting favorable market perception, which aligns with the generally positive outcome from the Validea fundamental screen.

Key Decisions for Investors

• Investors employing a long-term, fundamentally-driven strategy akin to Warren Buffett's may consider Zoetis Inc. for further due diligence, given its favorable rating and strength in areas like earnings predictability and free cash flow.
• A critical point for investigation is the company's failure on the 'Return on Total Capital' metric; understanding the underlying reasons for this specific underperformance is essential before making an investment decision.
• Investors should monitor ZTS's efforts to improve its return on total capital, as addressing this weakness could significantly enhance its appeal to value-focused investors and further validate the positive aspects highlighted by the Patient Investor model.